Cargando…
Luminescent multiplex viability assay for Trypanosoma brucei gambiense
BACKGROUND: New compounds for the treatment of human African trypanosomiasis (HAT) are urgently required. Trypanosoma brucei (T.b.) gambiense is the leading cause of HAT, yet T.b. gambiense is often not the prime target organism in drug discovery. This may be attributed to the difficulties in handli...
Autores principales: | Van Reet, Nick, Pyana, Pati, Rogé, Stijn, Claes, Filip, Büscher, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728213/ https://www.ncbi.nlm.nih.gov/pubmed/23856321 http://dx.doi.org/10.1186/1756-3305-6-207 |
Ejemplares similares
-
Isolation of Trypanosoma brucei gambiense from Cured and Relapsed Sleeping Sickness Patients and Adaptation to Laboratory Mice
por: Pyana, Patient Pati, et al.
Publicado: (2011) -
Melarsoprol Sensitivity Profile of Trypanosoma brucei gambiense Isolates from Cured and Relapsed Sleeping Sickness Patients from the Democratic Republic of the Congo
por: Pyana Pati, Patient, et al.
Publicado: (2014) -
Identification of Peptide Mimotopes of Trypanosoma brucei gambiense Variant Surface Glycoproteins
por: Van Nieuwenhove, Liesbeth Carolien, et al.
Publicado: (2011) -
Expression of Trypanosoma brucei gambiense Antigens in Leishmania tarentolae. Potential for Use in Rapid Serodiagnostic Tests (RDTs)
por: Rooney, Barrie, et al.
Publicado: (2015) -
Single nucleotide polymorphisms and copy-number variations in the Trypanosoma brucei repeat (TBR) sequence can be used to enhance amplification and genotyping of Trypanozoon strains
por: Van Reet, Nick, et al.
Publicado: (2021)